Group 1: Service Prices and CPI - February CPI year-on-year increased by 1.3%, the highest monthly growth in three years, boosted by the Spring Festival effect[5] - Service prices in February rose above seasonal levels, marking the highest increase for a Spring Festival month in five years[5] - The increase in service prices is attributed to a temporary price pulse from the extended holiday, which is expected to normalize post-February[10] Group 2: PPI Outlook - PPI year-on-year decline narrowed by 0.5 percentage points in February, driven by new price factors, marking the first positive change in 41 months[16] - The PPI is expected to turn positive in the second quarter, potentially earlier than mid-year due to rising international oil prices from geopolitical tensions[20] - The increase in PPI is supported by rising prices in the non-ferrous metals sector, with prices for related industries rising by 7.1% and 4.6% respectively[19] Group 3: Policy Space and Risks - Despite a recent rise in bond yields and a cooling of interest rate cut expectations, there remains ample policy space for adjustments[22] - The overall inflation pressure is manageable, allowing for potential policy maneuvers, especially as CPI is expected to decline in March[22] - Key risks include geopolitical tensions and unexpected surges in international oil prices[23]

Investment Rating - The report rates the industry as "Positive" [2][7] Core Insights - Small nucleic acid drugs represent the third major paradigm in modern pharmaceuticals, following small molecules and antibody drugs, with advantages such as broad target range, lasting efficacy, and direct research pathways [2][21] - The global small nucleic acid drug market is expected to grow from USD 7.1 billion in 2025 to USD 54.9 billion by 2034, with ASO and siRNA currently holding equal market shares [3][62] - Key players in the overseas market include Ionis, Sarepta, Alnylam, and Arrowhead, each leading in different therapeutic areas and technologies [4][62] Summary by Sections 1. Small Nucleic Acids: A New Era in Modern Pharmaceuticals - Small nucleic acid drugs intervene at the RNA level, offering a new approach to disease treatment with significant advantages over traditional therapies [21][24] - The main technical paths for sequence design are ASO and siRNA, with clinical trials for these types significantly outpacing others [42][62] 2. Acceleration of Global Commercialization in the Small Nucleic Acid Industry - The global small nucleic acid drug industry is characterized by a clear value distribution across the supply chain, with solid-phase synthesis as the preferred production method [3][62] - The number of clinical pipelines globally totals 327, with siRNA leading in quantity and a wide distribution of targets [3][62] 3. Overseas Giants Leading Technological Frontiers - Ionis is a pioneer in ASO technology, with a strong pipeline and successful product sales [4][62] - Alnylam is recognized as the global leader in siRNA, achieving profitability in 2025 with its top-selling drug Amvuttra [4][62] 4. Recommended Domestic Companies - The report suggests focusing on domestic companies such as Rebio, Bowang Pharmaceutical, Saint Gene, Frontier Biotech, Hengrui Medicine, China Biopharmaceutical, and CSPC [5][62]

Investment Rating - The report maintains a "Positive" investment rating for the clinical CRO industry [2] Core Insights - The clinical CRO industry is expected to enter a new growth cycle driven by improved supply-demand dynamics, with significant increases in order volume and pricing anticipated [3][5] - The domestic clinical CRO market is projected to reach a scale of 95.56 billion RMB by 2030, with a compound annual growth rate (CAGR) of approximately 13% from 2024 to 2030 [3][31] - The report highlights the increasing recognition of China's clinical trial quality on a global scale, suggesting that leading domestic CROs may expand internationally alongside innovative drug business development (BD) [3][38] Demand Summary - The demand for clinical CRO services is closely linked to the progress of clinical trials, with a notable recovery in innovative drug financing observed in 2025, where the financing amount reached 14.684 billion USD, a year-on-year increase of approximately 127% [3][17] - The number of clinical IND approvals in China for 2025 was 2,703, reflecting a year-on-year growth of about 19%, indicating a resurgence in clinical trial activities [3][27] - The report notes that the number of early-phase clinical trials (I and II) has also increased significantly, with I phase trials up by 13% and II phase trials up by 42% in 2025 [3][27] Supply Summary - The clinical CRO industry is characterized by a highly fragmented competitive landscape, with the leading company, Tigermed, holding only 12.8% market share as of 2023 [4][44] - The report indicates that many smaller companies are exiting the market due to previous demand shortages, leading to a consolidation of market share among larger players [4][46] - The average number of clinical trials per CRO company has increased by 20.6% year-on-year, indicating a trend towards greater concentration in the industry [4][55] Performance Tracking - The report anticipates a recovery in order prices for clinical CROs, with new order prices beginning to rise in 2025 after a period of decline [5][6] - The revenue trends for clinical CRO companies are showing signs of stabilization, with expectations for improved profitability as order prices recover [5][6] - Leading companies are expected to see significant improvements in their profit margins as new order prices increase [5][6] Recommended Companies - **Tigermed**: A leading global clinical CRO with a projected revenue of 6.66-7.68 billion RMB for 2025, representing a year-on-year growth of about 9% [7] - **Norse**: A specialized clinical CRO with a broad business scope, showing a year-on-year revenue growth of 24.48% in Q3 2025 [7] - **Prasis**: A leading SMO in China, with a significant increase in new contracts, showing a year-on-year growth of 40.12% in 2025 [7] - **Bohui Pharma**: Focused on one-stop R&D outsourcing, with a strong order reserve and consistent growth in new orders [7]

Investment Rating - The investment rating for China Tobacco Hong Kong (6055.HK) is not explicitly stated in the provided documents, but the overall performance and future outlook suggest a positive sentiment towards the stock [1]. Core Insights - The company reported a strong annual performance for 2025, achieving revenue of HKD 14.58 billion (up 11.5% year-on-year) and a net profit attributable to shareholders of HKD 980 million (up 21.7 year-on-year), with a net profit margin of 6.7% (up 0.6 percentage points) [1]. - The second half of 2025 saw a revenue of HKD 4.26 billion (down 2.5% year-on-year) and a net profit of HKD 270 million (up 30.2% year-on-year), indicating a recovery in profitability despite a slight decline in revenue [1]. - The company aims to accelerate its global expansion through both organic growth and acquisitions, with expectations for improved profitability driven by product structure optimization and market positioning [4]. Summary by Sections Financial Performance - The company experienced a robust revenue growth of 11.5% year-on-year, with a total revenue of HKD 14.58 billion for 2025. The net profit increased by 21.7% year-on-year to HKD 980 million, reflecting a net profit margin improvement [1][2]. - In the second half of 2025, the revenue was HKD 4.26 billion, showing a slight decline of 2.5% year-on-year, while the net profit surged by 30.2% to HKD 270 million, indicating strong operational efficiency [1][2]. Segment Analysis - **Tobacco Leaf Imports**: Revenue for H2 2025 was HKD 1.14 billion (down 21.5% year-on-year), with a gross margin of 7.5% (up 1.9 percentage points) [2]. - **Tobacco Leaf Exports**: Revenue reached HKD 1.33 billion (up 15.9% year-on-year), with a gross margin of 7.06% (up 2.2 percentage points) [2]. - **Cigarette Exports**: Revenue was HKD 1.11 billion (up 8.6% year-on-year), with a gross margin of 21.4% (up 6.2 percentage points) [3]. - **New Tobacco Exports**: Revenue fell to HKD 50 million (down 45.8% year-on-year), but the decline in sales volume is expected to narrow in the future [3]. - **Brazil Operations**: Revenue was HKD 630 million (down 3.5% year-on-year), with a gross margin of 16.9% (down 0.8 percentage points) [3]. Profit Forecast - The company anticipates net profits of HKD 1.13 billion, HKD 1.39 billion, and HKD 1.61 billion for 2026, 2027, and 2028, respectively, with corresponding price-to-earnings ratios of 23.6X, 19.2X, and 16.6X [4].

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the overall performance and future outlook suggest a positive sentiment towards the stock [1]. Core Insights - The company reported a strong annual performance with total revenue of HKD 14.58 billion, representing a year-on-year increase of 11.5%, and a net profit attributable to shareholders of HKD 980 million, up 21.7% year-on-year [1]. - The second half of the year showed a revenue of HKD 4.26 billion, a slight decline of 2.5% year-on-year, but net profit increased by 30.2% to HKD 270 million, indicating resilience in profitability [1]. - The company is focusing on both organic growth and external expansion to accelerate its global footprint, with expectations for a faster pace of mergers and acquisitions in the future [4]. Revenue Breakdown - **Tobacco Leaf Imports**: Revenue in H2 2025 was HKD 1.14 billion, down 21.5% year-on-year, with a gross margin of 7.5%, an increase of 1.9 percentage points [2]. - **Tobacco Leaf Exports**: H2 2025 revenue reached HKD 1.33 billion, up 15.9% year-on-year, with a gross margin of 7.06%, reflecting effective market strategies [2]. - **Cigarette Exports**: Revenue for H2 2025 was HKD 1.11 billion, an increase of 8.6% year-on-year, with a gross margin of 21.4%, benefiting from channel expansion and product optimization [3]. - **New Tobacco Exports**: Revenue fell to HKD 50 million, down 45.8% year-on-year, but showed signs of recovery with a significant quarter-on-quarter increase [3]. - **Brazil Operations**: Revenue was HKD 630 million, a slight decline of 3.5% year-on-year, with a gross margin of 16.9% [3]. Profit Forecast - The company anticipates net profits of HKD 1.13 billion, HKD 1.39 billion, and HKD 1.61 billion for the years 2026, 2027, and 2028, respectively, with corresponding price-to-earnings ratios of 23.6X, 19.2X, and 16.6X [4]. Financial Metrics - The projected total revenue for 2026 is HKD 15.63 billion, with a year-on-year growth rate of 7% [7]. - The expected net profit for 2026 is HKD 1.13 billion, reflecting a growth rate of 15% compared to 2025 [7]. - The earnings per share (EPS) for 2026 is projected to be HKD 1.63, with a price-to-earnings ratio of 23.64 [7].

Investment Rating - The industry investment rating is "Positive" [2] Core Insights - The electronic sub-industry has experienced significant adjustments recently, with the semiconductor sector showing a year-to-date increase of +9.93%, while consumer electronics have decreased by -4.34% [3][10] - AI ASIC demand is surging, with Broadcom's FY26Q1 revenue reaching $19.3 billion, a year-on-year increase of 29%, driven by a 106% growth in AI-related semiconductor revenue [3] - Marvell's FY26Q4 revenue hit $2.2 billion, a 22% year-on-year increase, with data center business contributing approximately 74% of total revenue, indicating strong growth potential in AI infrastructure [3] Summary by Sections Electronic Industry Performance - The electronic sub-industry has seen a significant adjustment, with various sectors experiencing different year-to-date performance metrics [3][10] - Notable declines in stock prices were observed among major North American companies, with TSMC down by -9.53% and Micron Technology down by -10.20% [3][11] Company-Specific Developments - Broadcom's AI semiconductor revenue is projected to reach approximately $10.7 billion in FY26Q2, indicating a robust growth trajectory in the AI ASIC market [3] - Marvell is transitioning towards becoming an "AI data center infrastructure platform company," with expectations of continued revenue acceleration in FY27 [3] Investment Recommendations - Suggested companies to watch include: Industrial Fulian, Huadian Co., Pengding Holdings, and Shenghong Technology for overseas AI; and Cambricon, Chipone, SMIC, and Huahong Semiconductor for domestic AI [3][4]

Core Insights - The report highlights that the ongoing geopolitical conflicts in the Middle East are the primary variable affecting market risk appetite, leading to a decline in global equity markets, a strengthening dollar, and a significant rise in oil prices. The trading logic is focused on defensive demand and rising energy prices, with a need to monitor the duration of oil supply constraints and their potential long-term impact on supply-demand dynamics [2][12][16]. - A combination of rising commodity prices and declining interest rates is seen as favorable for a bull market. Historically, instances of rising commodity prices coinciding with falling stock markets are rare, with only three occurrences since 1968. Overall, both US and A-shares benefit from rising commodity prices, unless inflation pressures lead to significant liquidity tightening [2][4][25]. - The report suggests that the current domestic deflationary pressures reduce concerns about negative inflation impacts, and interest rates are unlikely to rise significantly in the absence of further positive signals in the fundamentals. The combination of rising ROE and declining interest rates creates a conducive environment for the stock market [2][4][25]. Market Changes This Week - This week, major A-share indices experienced declines, with the Shanghai Composite Index down by 0.93%, and the ChiNext Index down by 2.45%. The sectors leading the gains included oil and petrochemicals (+8.06%), while media (-6.97%) and non-ferrous metals (-5.47%) faced significant losses [32][33]. - Global stock markets also saw declines, with the S&P 500 down by 2.02%. In the commodity market, NYMEX crude oil surged by 36.18%, while LME copper fell by 3.61% [33][34]. Policy and Economic Outlook - The report indicates that the policy tone from the Two Sessions is generally stable, with limited expectations for unexpected easing policies in the short term. The economic growth target for 2026 has been adjusted to a range of 4.5%-5%, with other policy targets remaining consistent with 2025 [3][14]. - The report emphasizes that structural support policies aligned with long-term economic quality improvement and transformation are expected to be implemented effectively, particularly in sectors like services, AI commercialization, and new infrastructure [3][13]. Investment Recommendations - The report suggests focusing on sectors such as non-ferrous metals, oil and petrochemicals, and basic chemicals, which are expected to benefit from the current market dynamics. The energy security narrative is likely to strengthen due to ongoing geopolitical tensions, creating opportunities in these sectors [28][31]. - The report also highlights the potential for structural support policies to continue benefiting sectors aligned with long-term economic development logic, such as technology and consumption [27][31].

Investment Rating - The report rates the oil processing industry as "Positive" [1] Core Insights - The escalation of the conflict between the US and Iran has led to a significant increase in international oil prices, with Brent and WTI prices reaching 92.69 and 90.90 USD per barrel respectively as of March 6, 2026 [2][9] - The report highlights a substantial rise in oil prices, with Brent increasing by 27.20% and WTI by 35.63% over the past week [2][24] - The oil and petrochemical sector has shown strong performance, with an 8.06% increase in the sector index, while the broader market (CSI 300) fell by 1.07% [10][13] Summary by Sections Oil Price Review - As of March 6, 2026, Brent crude futures settled at 92.69 USD/barrel, up 19.82 USD/barrel (+27.20%) from the previous week, while WTI crude futures settled at 90.90 USD/barrel, up 23.88 USD/barrel (+35.63%) [2][24] - The report notes that geopolitical tensions in the Middle East have exacerbated supply concerns, contributing to the price surge [9] Offshore Drilling Services - The number of global offshore self-elevating drilling rigs increased to 376, with a net addition of 1 rig, while floating drilling rigs rose to 134, with a net addition of 2 rigs [32] Oil Supply - As of February 27, 2026, US crude oil production was reported at 13.696 million barrels per day, a decrease of 0.06 million barrels per day from the previous week [39] - The number of active drilling rigs in the US increased to 411, up by 4 rigs [39] Oil Demand - US refinery crude processing increased to 15.841 million barrels per day, up by 0.18 million barrels per day, with a refinery utilization rate of 89.20%, an increase of 0.6 percentage points [49] Oil Inventory - As of February 27, 2026, total US crude oil inventories stood at 855 million barrels, an increase of 3.475 million barrels (+0.41%) from the previous week [57] - The report indicates that commercial crude oil inventories rose to 439 million barrels, up by 3.475 million barrels (+0.80%) [57] Related Companies - The report mentions several key companies in the sector, including China National Offshore Oil Corporation (CNOOC), China Petroleum & Chemical Corporation (Sinopec), and China National Petroleum Corporation (PetroChina) [3]

1. Report Industry Investment Rating - The investment rating for the electronics industry is "Bullish" [2] 2. Core Viewpoints of the Report - This week, the electronics sub - industries have undergone significant adjustments. The year - to - date and weekly percentage changes of the Shenwan Electronics secondary indices vary among different sub - industries. North American important stocks mostly declined this week. The demand for AI ASIC has exploded, with Broadcom's performance and guidance exceeding expectations. Marvell's revenue driven by the data center and AI has reached a new high, and its growth potential is strengthening. It is recommended to pay attention to overseas AI - related, domestic AI - related, and storage - related stocks [3] 3. Summary by Relevant Catalogs 3.1 Market Tracking - **Electronics Industry**: The year - to - date percentage changes of Shenwan Electronics secondary indices are: Semiconductors (+9.93%), Other Electronics II (+8.61%), Components (+7.63%), Optoelectronics (+8.93%), Consumer Electronics (-4.34%), and Electronic Chemicals II (+18.42%). The weekly percentage changes are: Semiconductors (-5.57%), Other Electronics II (-4.08%), Components (-4.79%), Optoelectronics (-2.26%), Consumer Electronics (-5.40%), and Electronic Chemicals II (-6.21%) [3][10] - **Stock Price Changes**: Most North American important stocks declined this week. The year - to - date and weekly percentage changes of important technology stocks in the US stock market are provided. For example, Apple's year - to - date change is -5.30% and this week's change is -2.54% [3][11] 3.2 Individual Stock Price Changes - **Semiconductor Sector**: This week, Parylene Co., Ltd., BAW Storage Co., Ltd., Yuanjie Technology Co., Ltd., Demingli Co., Ltd., and Jiangbo Long Co., Ltd. had relatively high increases, with year - on - year increases of +38.17%, +26.25%, +10.52%, +5.93%, and +4.90% respectively. Oulexin Material Co., Ltd., Juguang Technology Co., Ltd., Kaide Quartz Co., Ltd., Ashi Chuang Co., Ltd., and Aojie Technology Co., Ltd. had relatively large declines, with year - on - year decreases of -20.26%, -20.17%, -16.00%, -15.28%, and -15.24% respectively [17][18] - **Consumer Electronics Sector**: This week, Suzhou Tianmai Co., Ltd., Jiemei Te Co., Ltd., Wanxiang Technology Co., Ltd., Hongri Da Co., Ltd., and Jiebang Technology Co., Ltd. had relatively high increases, with year - on - year increases of +34.12%, +16.62%, +8.46%, +6.07%, and +4.18% respectively. Jierong Technology Co., Ltd., Huanxu Electronics Co., Ltd., Tonglian Precision Co., Ltd., Kesen Technology Co., Ltd., and Yunzhong Technology Co., Ltd. had relatively large declines, with year - on - year decreases of -18.96%, -17.22%, -16.87%, -14.36%, and -14.29% respectively [18][19] - **Component Sector**: This week, Kexiang Co., Ltd., Xunjiexing Co., Ltd., Zhongying Technology Co., Ltd., Dongshan Precision Co., Ltd., and Chaoying Electronics Co., Ltd. had relatively high increases, with year - on - year increases of +23.26%, +18.80%, +12.43%, +11.57%, and +10.40% respectively. Shiyun Circuit Co., Ltd., Huazheng New Materials Co., Ltd., Dalikai Pu Co., Ltd., Pengding Holdings Co., Ltd., and Hudian Co., Ltd. had relatively large declines, with year - on - year decreases of -14.88%, -13.64%, -11.02%, -9.82%, and -9.80% respectively [19][20] - **Optoelectronics Sector**: This week, Huacan Optoelectronics Co., Ltd., Jufei Optoelectronics Co., Ltd., Tianlu Technology Co., Ltd., Yashi Optoelectronics Co., Ltd., and Huasu Holdings Co., Ltd. had relatively high increases, with year - on - year increases of +35.84%, +17.35%, +16.14%, +14.10%, and +13.03% respectively. Huichuangda Co., Ltd., Heli Tai Co., Ltd., Kaisheng Technology Co., Ltd., Gebijia Co., Ltd., and Fujing Technology Co., Ltd. had relatively large declines, with year - on - year decreases of -18.00%, -12.62%, -11.24%, -10.85%, and -10.67% respectively [21][22] - **Electronic Chemicals Sector**: This week, Jinhong Gas Co., Ltd., Siquan New Materials Co., Ltd., Laite Optoelectronics Co., Ltd., Puyang Huicheng Co., Ltd., and Sanfu New Materials Co., Ltd. had relatively high increases, with year - on - year increases of +6.77%, +3.15%, +2.58%, +0.89%, and +0.83% respectively. Tongyu New Materials Co., Ltd., Qiangli New Materials Co., Ltd., Jingrui Electric Materials Co., Ltd., Feikai Materials Co., Ltd., and Rongda Photosensitive Co., Ltd. had relatively large declines, with year - on - year decreases of -14.08%, -11.21%, -10.71%, -10.58%, and -10.28% respectively [22][23] 3.3 Company Performance Analysis - **Broadcom**: In FY26Q1, it achieved revenue of $19.3 billion, a year - on - year increase of 29%, higher than the market expectation of $19.26 billion. AI - related semiconductor revenue reached $8.4 billion, a year - on - year increase of 106%. The company expects FY26Q2 revenue to be about $22 billion (a year - on - year increase of 47%), and AI semiconductor revenue will further increase to about $10.7 billion [3] - **Marvell**: In FY26Q4, it achieved revenue of $2.2 billion, a year - on - year increase of 22%, and Non - GAAP EPS was $0.80. The full - year FY26 revenue reached $8.2 billion, a year - on - year increase of 42%. The data center business accounts for about 74%. The company expects revenue in each quarter of FY27 to continue to grow at an accelerating rate and predicts that FY27 Q1 revenue will be about $2.4 billion [3] 3.4 Stock Recommendations - **Overseas AI - related Stocks**: Foxconn Industrial Internet Co., Ltd., Hudian Co., Ltd., Pengding Holdings Co., Ltd., Shenghong Technology Co., Ltd., Shengyi Technology Co., Ltd., Shengyi Electronics Co., Ltd., etc. - **Domestic AI - related Stocks**: Cambricon Technologies Corporation Limited, Xin Yuan Co., Ltd., SMIC, Huahong Semiconductor Limited, Shennan Circuits Co., Ltd., etc. - **Storage - related Stocks**: GigaDevice Semiconductor Inc., Puren Co., Ltd., Dongxin Co., Ltd., Hengshuo Co., Ltd., Demingli Co., Ltd., Jiangbo Long Co., Ltd., etc. [3][4]

Investment Rating - The report does not specify a direct investment rating for the industry but emphasizes a positive outlook on green transformation and ESG initiatives [2][3]. Core Insights - The government is accelerating the comprehensive green transition, focusing on carbon peak and carbon neutrality as key drivers for reducing carbon emissions, pollution, and promoting green growth [3][12]. - The establishment of a national low-carbon transition fund aims to foster new growth points such as hydrogen and green fuels, while effectively managing high energy-consuming and high-emission projects [3][12]. - The report highlights the importance of a dual control system for carbon emissions, focusing on both total emissions and intensity, to prevent rebound effects during economic recovery [8][44]. Summary by Sections Domestic Focus - The government work report emphasizes the need for comprehensive ecological environment governance, including air quality improvement plans and pollution control in key industries [3][12]. - It outlines the promotion of a green low-carbon economy through policy enhancements and the establishment of zero-carbon parks and factories [3][12]. - The report also mentions the importance of biodiversity protection and the integration of various ecological systems for sustainable development [3][12]. International Focus - The Net Zero Asset Managers Initiative was re-established with over 250 asset managers joining, providing a platform for public disclosure of net-zero commitments [4][18]. - The report discusses the IFRS's release of guidelines to assist jurisdictions in applying ISSB standards for sustainable financial information disclosure [19][20]. ESG Financial Products Tracking - As of March 8, 2026, China has issued 3,955 ESG bonds with a total scale of 5.77 trillion RMB, where green bonds account for 62.17% of the total [5][30]. - The market has 1,090 existing ESG products with a total net value of 17,597.86 billion RMB, with socially responsible products making up 41.67% [5][36]. - There are 1,235 existing ESG bank wealth management products, with pure ESG products constituting 53.28% of the total [5][41]. Index Tracking - As of March 6, 2026, major ESG indices, except for the CSI 300 ESG Leaders, underperformed the market, with the Wind All A Sustainable ESG index showing the largest decline of 1.33% [7][42]. - Over the past year, major ESG indices have generally increased, with the Shenzhen ESG 300 index rising by 20.69% [7][42]. Expert Opinions - An expert from Renmin University highlights the shift from energy consumption intensity to carbon emission intensity as a more effective approach to achieving carbon peak goals [8][44]. - The expert emphasizes the need for improved systems and data disclosure to ensure that carbon reduction targets are actionable and executable [8][44].